Survivin is highly expressed in CD34 +38 - leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

Bing Z. Carter, Yihua Qiu, Xuelin Huang, Lixia Diao, Nianxiang Zhang, Kevin R. Coombes, Duncan H. Mak, Marina Konopleva, Jorge Cortes, Hagop M. Kantarjian, Gordon Mills, Michael Andreeff, Steven M. Kornblau

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Survivin, a member of the inhibitors of apoptosis protein family, plays important roles in cell proliferation and survival and is highly expressed in various malignancies, including leukemias. To better understand its role in acute myeloid leukemia (AML), we profiled survivin expression in samples obtained from 511 newly diagnosed AML patients and in CD34 +38 - AML stem/progenitor cells using a validated reverse-phase protein array; we correlated its levels with clinical outcomes and with levels of other proteins in the same sample set. We found that survivin levels were higher in bone marrow than in paired peripheral blood leukemic cells (n = 140, P = .0001) and that higher survivin levels significantly predicted shorter overall (P = .016) and event-free (P = .023) survival in multivariate Cox model analysis. Importantly, survivin levels were significantly higher in CD34 +38 - AML stem/progenitor cells than in bulk blasts and total CD34 + AML cells (P < .05). Survivin expression correlated with the expressions of multiple proteins involved with cell proliferation and survival. Particularly, its expression strongly correlated with HIF1α in the stem/progenitor cell compartment. These results suggest that survivin is a prognostic biomarker in AML and that survivin, which is overexpressed in AML stem/progenitor cells, remains a potentially important target for leukemia therapy.

Original languageEnglish (US)
Pages (from-to)173-180
Number of pages8
JournalBlood
Volume120
Issue number1
DOIs
StatePublished - Jul 5 2012
Externally publishedYes

Fingerprint

Stem cells
Acute Myeloid Leukemia
Stem Cells
Cell proliferation
Inhibitor of Apoptosis Proteins
Proteins
Biomarkers
Cell Survival
Bone
Leukemia
Blood
Cell Proliferation
Protein Array Analysis
Myeloid Cells
Proportional Hazards Models
Blood Cells
Bone Marrow
Survival
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Carter, B. Z., Qiu, Y., Huang, X., Diao, L., Zhang, N., Coombes, K. R., ... Kornblau, S. M. (2012). Survivin is highly expressed in CD34 +38 - leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood, 120(1), 173-180. https://doi.org/10.1182/blood-2012-02-409888

Survivin is highly expressed in CD34 +38 - leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. / Carter, Bing Z.; Qiu, Yihua; Huang, Xuelin; Diao, Lixia; Zhang, Nianxiang; Coombes, Kevin R.; Mak, Duncan H.; Konopleva, Marina; Cortes, Jorge; Kantarjian, Hagop M.; Mills, Gordon; Andreeff, Michael; Kornblau, Steven M.

In: Blood, Vol. 120, No. 1, 05.07.2012, p. 173-180.

Research output: Contribution to journalArticle

Carter, BZ, Qiu, Y, Huang, X, Diao, L, Zhang, N, Coombes, KR, Mak, DH, Konopleva, M, Cortes, J, Kantarjian, HM, Mills, G, Andreeff, M & Kornblau, SM 2012, 'Survivin is highly expressed in CD34 +38 - leukemic stem/progenitor cells and predicts poor clinical outcomes in AML', Blood, vol. 120, no. 1, pp. 173-180. https://doi.org/10.1182/blood-2012-02-409888
Carter, Bing Z. ; Qiu, Yihua ; Huang, Xuelin ; Diao, Lixia ; Zhang, Nianxiang ; Coombes, Kevin R. ; Mak, Duncan H. ; Konopleva, Marina ; Cortes, Jorge ; Kantarjian, Hagop M. ; Mills, Gordon ; Andreeff, Michael ; Kornblau, Steven M. / Survivin is highly expressed in CD34 +38 - leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. In: Blood. 2012 ; Vol. 120, No. 1. pp. 173-180.
@article{f7f8962b2fa9476d8345d6623e9ba8d6,
title = "Survivin is highly expressed in CD34 +38 - leukemic stem/progenitor cells and predicts poor clinical outcomes in AML",
abstract = "Survivin, a member of the inhibitors of apoptosis protein family, plays important roles in cell proliferation and survival and is highly expressed in various malignancies, including leukemias. To better understand its role in acute myeloid leukemia (AML), we profiled survivin expression in samples obtained from 511 newly diagnosed AML patients and in CD34 +38 - AML stem/progenitor cells using a validated reverse-phase protein array; we correlated its levels with clinical outcomes and with levels of other proteins in the same sample set. We found that survivin levels were higher in bone marrow than in paired peripheral blood leukemic cells (n = 140, P = .0001) and that higher survivin levels significantly predicted shorter overall (P = .016) and event-free (P = .023) survival in multivariate Cox model analysis. Importantly, survivin levels were significantly higher in CD34 +38 - AML stem/progenitor cells than in bulk blasts and total CD34 + AML cells (P < .05). Survivin expression correlated with the expressions of multiple proteins involved with cell proliferation and survival. Particularly, its expression strongly correlated with HIF1α in the stem/progenitor cell compartment. These results suggest that survivin is a prognostic biomarker in AML and that survivin, which is overexpressed in AML stem/progenitor cells, remains a potentially important target for leukemia therapy.",
author = "Carter, {Bing Z.} and Yihua Qiu and Xuelin Huang and Lixia Diao and Nianxiang Zhang and Coombes, {Kevin R.} and Mak, {Duncan H.} and Marina Konopleva and Jorge Cortes and Kantarjian, {Hagop M.} and Gordon Mills and Michael Andreeff and Kornblau, {Steven M.}",
year = "2012",
month = "7",
day = "5",
doi = "10.1182/blood-2012-02-409888",
language = "English (US)",
volume = "120",
pages = "173--180",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Survivin is highly expressed in CD34 +38 - leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

AU - Carter, Bing Z.

AU - Qiu, Yihua

AU - Huang, Xuelin

AU - Diao, Lixia

AU - Zhang, Nianxiang

AU - Coombes, Kevin R.

AU - Mak, Duncan H.

AU - Konopleva, Marina

AU - Cortes, Jorge

AU - Kantarjian, Hagop M.

AU - Mills, Gordon

AU - Andreeff, Michael

AU - Kornblau, Steven M.

PY - 2012/7/5

Y1 - 2012/7/5

N2 - Survivin, a member of the inhibitors of apoptosis protein family, plays important roles in cell proliferation and survival and is highly expressed in various malignancies, including leukemias. To better understand its role in acute myeloid leukemia (AML), we profiled survivin expression in samples obtained from 511 newly diagnosed AML patients and in CD34 +38 - AML stem/progenitor cells using a validated reverse-phase protein array; we correlated its levels with clinical outcomes and with levels of other proteins in the same sample set. We found that survivin levels were higher in bone marrow than in paired peripheral blood leukemic cells (n = 140, P = .0001) and that higher survivin levels significantly predicted shorter overall (P = .016) and event-free (P = .023) survival in multivariate Cox model analysis. Importantly, survivin levels were significantly higher in CD34 +38 - AML stem/progenitor cells than in bulk blasts and total CD34 + AML cells (P < .05). Survivin expression correlated with the expressions of multiple proteins involved with cell proliferation and survival. Particularly, its expression strongly correlated with HIF1α in the stem/progenitor cell compartment. These results suggest that survivin is a prognostic biomarker in AML and that survivin, which is overexpressed in AML stem/progenitor cells, remains a potentially important target for leukemia therapy.

AB - Survivin, a member of the inhibitors of apoptosis protein family, plays important roles in cell proliferation and survival and is highly expressed in various malignancies, including leukemias. To better understand its role in acute myeloid leukemia (AML), we profiled survivin expression in samples obtained from 511 newly diagnosed AML patients and in CD34 +38 - AML stem/progenitor cells using a validated reverse-phase protein array; we correlated its levels with clinical outcomes and with levels of other proteins in the same sample set. We found that survivin levels were higher in bone marrow than in paired peripheral blood leukemic cells (n = 140, P = .0001) and that higher survivin levels significantly predicted shorter overall (P = .016) and event-free (P = .023) survival in multivariate Cox model analysis. Importantly, survivin levels were significantly higher in CD34 +38 - AML stem/progenitor cells than in bulk blasts and total CD34 + AML cells (P < .05). Survivin expression correlated with the expressions of multiple proteins involved with cell proliferation and survival. Particularly, its expression strongly correlated with HIF1α in the stem/progenitor cell compartment. These results suggest that survivin is a prognostic biomarker in AML and that survivin, which is overexpressed in AML stem/progenitor cells, remains a potentially important target for leukemia therapy.

UR - http://www.scopus.com/inward/record.url?scp=84863574448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863574448&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-02-409888

DO - 10.1182/blood-2012-02-409888

M3 - Article

C2 - 22645176

AN - SCOPUS:84863574448

VL - 120

SP - 173

EP - 180

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -